Korro Bio, Inc. (KRRO) Balance Sheet

The decline in total assets is driven overwhelmingly by cash depletion rather than asset build-out, which suggests the company is funding persistent operating losses from its existing capital base. Equity has contracted from $198.1M to $103.2M over the same window, reflecting accumulated deficit growth that has pushed retained earnings to -$422.4M. Investors should monitor whether the trajectory reflects a deliberate funding runway or an unsustainable draw on reserves.

The headline current ratio of 9.55 appears strong but is inflated by a small liability base relative to current assets, and it does not reflect the speed at which cash is being consumed. Cash has fallen from $61.7M in 2026Q1 to $24.9M in 2026Q2, a sharp reduction that warrants close monitoring. Based on these figures, the company's near-term liquidity position appears highly sensitive to any further delay in financing or adverse development outcomes.

Debt-to-equity has risen from 0.19 in 2024Q2 to 0.41 in 2026Q2 as equity has shrunk faster than debt, which suggests leverage is increasing mechanically rather than through strategic borrowing. The debt load remains stable in absolute terms at roughly $36M to $45M across the window, so the concern is less about the size of obligations and more about the declining capacity to service them from operations. Refinancing or repayment terms are not visible in the supplied data and warrant further investigation.

The steady expansion of the accumulated deficit by roughly $20M to $50M per quarter indicates that equity is being eroded by operating and non-operating losses. Because book equity is falling alongside the deficit, the company's equity cushion is shrinking in real terms rather than being replenished by earnings. The data does not show share issuance details, so dilution effects cannot be assessed from the balance sheet alone.